---
title: "Burning Rock CanCatch Custom MRD kit enters NMPA innovative device special review procedure"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296933190.md"
description: "Burning Rock's CanCatch Custom MRD kit entered China’s NMPA special review procedure for innovative medical devices on Aug. 25, 2026. It is the first tumor-informed personalized MRD kit in China using whole-exome sequencing for baseline profiling. Citing MEDAL study data, Burning Rock reported a 0.0036% limit of detection, 96.6% negative predictive value, and an average lead time of 299 days over imaging."
datetime: "2026-08-25T15:06:23.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296933190.md)
  - [en](https://longbridge.com/en/news/296933190.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296933190.md)
generator: "portal-rs"
---

# Burning Rock CanCatch Custom MRD kit enters NMPA innovative device special review procedure

-   Burning Rock’s CanCatch Custom Kit entered China’s NMPA special review procedure for innovative medical devices on Aug. 25, 2026. \* It is the first tumor-informed personalized MRD kit in China to use whole-exome sequencing for baseline profiling. \* Burning Rock cited MEDAL study data showing 0.0036% LOD, 96.6% NPV, with MRD detection leading imaging by 299 days on average. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Burning Rock Biotech Ltd. published the original content used to generate this news brief on August 25, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [BNR.US](https://longbridge.com/en/quote/BNR.US.md)

## Related News & Research

- [Burning Rock MRD kit enters China NMPA innovative device fast-track review](https://longbridge.com/en/news/298472255.md)
- [Burning Rock Biotech Q3 non-GAAP EPS of RMB -$0.17, revenue of RMB $134.77M](https://longbridge.com/en/news/298615146.md)
- [ALLO: Cema-cel and ALLO-329 advance with strong data, broad MRD adoption, and robust financial runway](https://longbridge.com/en/news/298469365.md)
- [Imunon sets R&D Day to spotlight IMNN-001 clinical progress](https://longbridge.com/en/news/298458567.md)
- [IceCure wins China NMPA approval to market ProSense cryoablation system](https://longbridge.com/en/news/298589959.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**